Search

Your search keyword '"Ardavanis A"' showing total 846 results
Start Over Author "Ardavanis A"
846 results on '"Ardavanis A"'

2. Living with breast cancer: Patients’ journey within the Greek National Health System

Author

Kaitelidou Daphne, Kalogeropoulou Maria, Katostaras Theofanis, Konstantakopoulou Olympia, Minogiannis Panagiotis, Skitsou Alexandra, Siskou Olga, Charalampous Georgios, Ardavanis Alexandros, and Liaropoulos Lykourgos

Subjects
process mapping, patients’ journey, breast cancer patients, waiting times, hospital staff’s views, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Process mapping (a patient-centred method) and recording the medical, nursing and administrative staff’s views involved in the provision of care help us understand patients’ experience regarding the constraints, delays and bottlenecks of healthcare service processes and identify areas of improvement.

Published
2015
Full Text
View/download PDF

4. Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study

Author

Dimitra Galiti, Helena Linardou, Sofia Agelaki, Athanasios Karampeazis, Nikolaos Tsoukalas, Amanda Psyrri, Michalis Karamouzis, Konstantinos N. Syrigos, Alexandros Ardavanis, Ilias Athanasiadis, Eleni Arvanitou, Stavroula Sgourou, Anastasia Mala, Christos Vallilas, and Ioannis Boukovinas

Subjects
cancer, digital health, patients’ characteristics, age, educational disparities, socioeconomic issues, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: The increasing burden of cancer, the development of novel therapies, and the COVID-19 pandemic have made cancer care more complex. Digital innovation was then pushed toward developing platforms to facilitate access to cancer care. Age, education, and other disparities were, however, shown to limit the use of the digital health innovation. The aim of this early-stage feasibility study was to assess whether Greek cancer patients would register at CureCancer and self-report their demographics, disease and therapy characteristics, and socioeconomic issues. The study was organized by the Hellenic Society of Medical Oncology. Methods: Patients from nine cancer centers were invited to register on the CureCancer platform and complete an anonymous questionnaire on demographics, disease and therapy characteristics, and socioeconomic issues. Patients were also encouraged to upload, in a secure area for them, their medical files and share them with their physicians. They were then asked to comment on their experience of registration and how easy it was to upload their medical files. Results: Of the 159 patients enrolled, 144 (90.56%) registered, and 114 of those (79.16%) completed the questionnaire, suggesting that the study is feasible. Users’ median age was 54.5 years, and 86.8% of them were university and high school graduates. Most patients (79.8%) reported their specific type of cancer diagnosis, and all reported their therapy characteristics. Breast and lung cancers were the most common. A total of 87 patients (76.3%) reported being on active cancer therapy, 46 (40.4%) had metastatic disease, and 51 (44.7%) received supportive care medications. Eighty-one (71.05%) patients received prior cancer therapies, and twenty-seven recalled prior supportive care medications. All patients reported visiting non-oncology Health Care Professionals during the study. Nineteen of 72 (26.39%) patients who worked prior to cancer diagnosis changed work status; 49 (42.98) patients had children under 24 years; and 16 (14%) patients lived alone. Nine (7.9%) patients were members of patient associations. Registration was “much/very much” easy for 98 (86.0%) patients, while 67 (58.8%) had difficulties uploading their files. Patients commented on the well-organized data access, improved communication, feeling safe, medication adherence, interventions from a distance, and saving time and money. Over 80% of patients “preferred the digital way”. Discussion: A total of 114 patients succeeded in registering on the digital platform and reporting their demographics, disease and therapy characteristics, and socioeconomic issues. Age and educational disparities were disclosed and highlighted the need for educational programs to help older people and people of lower education use digital innovation. Health care policy measures would support patients’ financial burden associated with work changes, living alone, and children under 24 years old at school or college. Policy actions would motivate patients to increase their participation in patient associations. According to the evidence DEFINED framework, the number of patients, and the focus on enrollment, engagement, and user experience, the study fulfills actionability level criterion 1.

Published
2023
Full Text
View/download PDF

5. Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

Author

Sykoutri Despina, Kardara Evgenia, Karagiannis Athanasios, Malliou Savvoula, Kountourakis Panteleimon, Doufexis Dimitrios, Ardavanis Alexandros, Charalampia Margari, and Rigatos Gerasimos

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Targeting angiogenesis is nowadays one of the most promising approaches for breast cancer. Bevacizumab (BEV), a VEGF-trap monoclonal antibody, was recently approved in combination with paclitaxel (PAC) for the first line treatment of advanced breast cancer (ABC). The activity of this combination in pretreated patients is not known. Methods Patients with pretreated ABC and progressive disease received BEV 10 mg/kg with PAC 135 mg/m2 every two weeks for six months and then maintenance with BEV 15 mg/kg every three weeks until progression. This regimen was chosen for better patient convenience, while maintaining the same dose intensity for both drugs. Results 42 patients were reviewed retrospectively (41 f, 1 m, mean age 57 years). Overall response rate was 35.7%. Stable disease was observed in 45.2% of patients, whereas 14.3% of patients progressed. The median overall survival was greater than 20 months, with a one year rate of 83.4%. The median progression free survival was 12.1 months, with a one year rate of 51.8%. Toxicity was in general acceptable. Conclusion This biweekly BEV/PAC combination seems to be active with acceptable toxicity in pretreated ABC with an advantage over the weekly regimen regarding quality of life and preservation of resources.

Published
2009
Full Text
View/download PDF

6. Use of expandable corpectomy trial and cage for reduction of neurofibromatosis associated cervical swan neck deformity

Author

CPT Michael W Patt, CPT Kyle S Ardavanis, LTC Daniel G Kang, and MAJ Daniel J Coughlin

Subjects
Neurofibromatosis type 1, Cervical swan neck deformity, Cervical kyphosis, Myelopathy, Expandable corpectomy cage, Surgery, RD1-811, Neurology. Diseases of the nervous system, RC346-429
Abstract

Originally recognized by German pathologist Frederick von Recklinghausen in 1882, neurofibromatosis type I (NF1) is an autosomal dominant disease generated from pathogenic mutation in the NF gene on chromosome 17q11.2 that affects approximately 1 in 3,000. The incidence of cervical spine abnormality in patients with NF1 is not well defined as frequently patients are asymptomatic. Severe cervical spine deformity in NF1 is currently only reported on the case series and case report level. Included in these series are cases of cervical swan neck deformity (CSND). Since their introduction in the early 2000 s, expandable corpectomy implant technology has demonstrated their efficacy in reconstruction of the cervical spine and has been used to treat trauma, metastases, myelopathy, and cervical deformity. We describe a novel technique for use in reduction and reconstruction in NF1 associated CSND including caspar pin distraction, cervical traction and serial expansion of an expandable corpectomy trial.

Published
2023
Full Text
View/download PDF

7. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

Author

Mountzios, Giannis, Planchard, David, Metro, Giulio, Tsiouda, Dora, Prelaj, Arsela, Lampaki, Sofia, Shalata, Walid, Riudavets, Mariona, Christopoulos, Petros, Girard, Nicolas, Albarrán-Artahona, Víctor, Garcia Campelo, Rosario, Samitas, Konstantinos, Banna, Giuseppe Luigi, Boukovinas, Ioannis, Agbarya, Abed, Koumarianou, Anna, Perdikouri, Eleni-Isidora, Kosmidis, Paris, Linardou, Helena, Mauri, David, Mavroudis, Dimitrios, Athanasiadis, Ilias, Kalofonos, Haralambos, Xenidis, Nikolaos, Korantzis, Ippokratis, Ardavanis, Alexandros, Rallis, Grigorios, Bottiglieri, Achille, Efthymiadis, Konstantinos, Oikonomopoulos, Georgios, Kokkalis, Alexandros, Saloustros, Emmanouil, Tsoukalas, Nikolaos, Bartzi, Dimitra, Economopoulou, Panagiota, Psyrri, Amanda, Reck, Martin, and Lo Russo, Giuseppe

Published
2023
Full Text
View/download PDF

9. 113P Real-world data from patients with osteosarcoma treated in 4 medical centers in Greece: Ninety percent or greater tumor necrosis is associated with disease-free survival

Author

Moutafi, M., primary, Kyriazoglou, A., additional, Kotsantis, I., additional, Kokkali-Zervos, S., additional, Antonopoulou, P., additional, Ardavanis, G., additional, Magkou, E., additional, Georgaki, E., additional, Anastasiou, M., additional, Pantazopoulos, A., additional, Boulouta, A., additional, Kirkasiadou, M., additional, Gavrielatou, N., additional, Economopoulou, P., additional, Ardavanis, A., additional, Boukovinas, I., additional, and Psyrri, A., additional

Published
2024
Full Text
View/download PDF

10. DP CHALLENGES IN ANA PLATFORM JACKET INSTALLATION

Author

Kimon Ardavanis, Radoslav Nabergoj, and Francesco Mauro

Subjects
offshore installation, dynamic positioning, multibody dynamics, Naval architecture. Shipbuilding. Marine engineering, VM1-989
Abstract

Installation of jacket platforms requires simultaneous and combined operations of multiple assets. Once the whole process has to be planned, it is necessary to predict in a fast and reliable way the possible weather limitations that may occur during the operations. The paper will present the major challenges of this unusual and innovative Dynamic Positioning analysis which has been carried out for Ana Jacket installation. The obtained results show that the Dynamic Positioning system of the core vessel in intact configuration is capable to hold the position for the investigated vessels' arrangements and design operative weather conditions. Lifting, upending and installation of Ana Jacket were carried out successfully in 2021.

Published
2022
Full Text
View/download PDF

11. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

Author

Giannis Mountzios, MD, PhD, David Planchard, MD, PhD, Giulio Metro, MD, PhD, Dora Tsiouda, Arsela Prelaj, MD, Sofia Lampaki, MD, PhD, Walid Shalata, MD, Mariona Riudavets, Petros Christopoulos, MD, PhD, Nicolas Girard, MD, PhD, Víctor Albarrán-Artahona, Rosario Garcia Campelo, MD, PhD, Konstantinos Samitas, MD, PhD, Giuseppe Luigi Banna, MD, Ioannis Boukovinas, MD, PhD, Abed Agbarya, MD, PhD, Anna Koumarianou, MD, Eleni-Isidora Perdikouri, Paris Kosmidis, Helena Linardou, MD, PhD, David Mauri, MD, PhD, Dimitrios Mavroudis, MD, PhD, Ilias Athanasiadis, MD, PhD, Haralambos Kalofonos, Nikolaos Xenidis, MD, PhD, Ippokratis Korantzis, MD, Alexandros Ardavanis, Grigorios Rallis, MD, Achille Bottiglieri, Konstantinos Efthymiadis, MD, Georgios Oikonomopoulos, MD, Alexandros Kokkalis, MD, Emmanouil Saloustros, MD, PhD, Nikolaos Tsoukalas, MD, Dimitra Bartzi, MD, Panagiota Economopoulou, Amanda Psyrri, MD, PhD, Martin Reck, and Giuseppe Lo Russo, MD, PhD

Subjects
Non–small-cell lung cancer, Epidermal growth factor receptor, Exon 20, Real-world data, Exotic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European registry for patients with advanced EGFR exon 20-mutant NSCLC diagnosed from January 2019 to December 2021. Patients enrolled in clinical trials were excluded. Clinicopathologic and molecular epidemiology data were collected, and treatment patterns were recorded. Clinical end points according to treatment assignment were assessed using Kaplan-Meier curves and Cox regression models. Results: Data on 175 patients from 33 centers across nine countries were included in the final analysis. Median age was 64.0 (range: 29.7–87.8) years. Main features included female sex (56.3%), never or past smokers (76.0%), adenocarcinoma (95.4%), and tropism for bone (47.4%) and brain (32.0%) metastases. Mean programmed death-ligand 1 tumor proportional score was 15.8% (range: 0%–95%) and mean tumor mutational burden was 7.06 (range: 0–18.8) mutations per megabase. Exon 20 was detected in the tissue (90.7%), plasma (8.7%), or both (0.6%), using mostly targeted next-generation sequencing (64.0%) or polymerase chain reaction (26.0%). Mutations were mainly insertions (59.3%), followed by duplications (28.1%), deletions-insertions (7.7%), and the T790M (4.5%). Insertions and duplications were located mainly in the near loop (codons 767–771, 83.1%) and the far loop (codons 771–775, 13%) and only in 3.9% within the C helix (codons 761–766). Main co-alterations included mutations in TP53 (61.8%) and MET amplifications (9.4%). Treatment on mutation identification included chemotherapy (CT) (33.8%), CT-immunotherapy (IO) (18.2%), osimertinib (22.1%), poziotinib (9.1%), mobocertinib (6.5%), mono-IO (3.9%), and amivantamab (1.3%). Disease control rates were 66.2% with CT plus or minus IO, 55.8% with osimertinib, 64.8% with poziotinib, and 76.9% with mobocertinib. Corresponding median overall survival was 19.7, 15.9, 9.2, and 22.4 months, respectively. In multivariate analysis, type of treatment (new targeted agents versus CT ± IO) affected progression-free survival (p = 0.051) and overall survival (p = 0.03). Conclusions: EXOTIC represents the largest academic real-world evidence data set on EGFR exon 20-mutant NSCLC in Europe. Indirectly compared, treatment with new exon 20-targeting agents is likely to confer survival benefit than CT plus or minus IO.

Published
2023
Full Text
View/download PDF

14. MA01.03 Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies

Author

Tsoukalas, N.G., primary, Christopoulou, A., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, S., additional, Bokas, A., additional, Samelis, G., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Nikolakopoulos, A., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Aravantinos, G., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2023
Full Text
View/download PDF

15. Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers

Author

Stefania Kokkali, Anastasios Kyriazoglou, Elpida Mangou, Panagiota Economopoulou, Michail Panousieris, Amanda Psyrri, Alexandros Ardavanis, Nikolaos Vassos, and Ioannis Boukovinas

Subjects
osteosarcoma, Ewing sarcoma, bone sarcoma, cabozantinib, tyrosine kinase inhibitor, Medicine
Abstract

Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17–83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms.

Published
2023
Full Text
View/download PDF

16. Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance

Author

Sotirios P. Fortis, Michael Sofopoulos, Maria Goulielmaki, Niki Arnogiannaki, Alexandros Ardavanis, Sonia A. Perez, Angelos D. Gritzapis, and Constantin N. Baxevanis

Subjects
tumor microenvironment, acquired immune resistance, CD8+ T cells, FoxP3+ cells, CD163+ cells, breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Acquired immune resistance (AIR) describes a situation in which cancer patients who initially responded clinically to immunotherapies, after a certain period of time, progress with their disease. Considering that AIR represents a feedback response of the tumor against the immune attack generated during the course of immunotherapies, it is conceivable that AIR may also occur before treatment initiation as a mechanism to escape endogenous adaptive antitumor immunity (EAAI). In the present study, we assessed the EAAI in paraffin-embedded breast primary tumor tissue samples and drew correlations with the clinical outcomes. In particular, we analyzed densities of CD8+ cells as elements mediating antitumor cytotoxicity, and of CD163+ and FoxP3+ cells as suppressor elements. We found a direct correlation between the densities of CD8+ cells and of CD163+ and/or FoxP3+ cells in the vast majority of patients’ tumors. Importantly, the vast majority of patients whose tumors were overpopulated by CD8+ cells developed AIR, which was characterized by high intratumoral CD163+ and/or FoxP3+ cell densities and reduced overall survival (OS). We also showed that AIR depends on the levels of CD8+ cell-ratios in the tumor center to the invasive margin. Our data suggest that tumors develop AIR only when under a robust endogenous immune pressure.

Published
2022
Full Text
View/download PDF

17. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer

Author

Koumarianou, A., Makrantonakis, P., Zagouri, F., Papadimitriou, C., Christopoulou, A., Samantas, E., Christodoulou, C., Psyrri, A., Bafaloukos, D., Aravantinos, G., Papakotoulas, P., Baka, S., Andreadis, C., Alexopoulos, A., Bompolaki, I., Kampoli, Κ., Liori, S., Karvounis, K., and Ardavanis, A.

Published
2020
Full Text
View/download PDF

18. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

Author

Brown, II, Tommy A., Mittendorf, Elizabeth A., Hale, Diane F., Myers, III, John W., Peace, Kaitlin M., Jackson, Doreen O., Greene, Julia M., Vreeland, Timothy J., Clifton, G. Travis, Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Symanowski, J., Murray, James L., Ponniah, Sathibalan, Anastasopoulou, E. A., Pistamaltzian, N. F., Baxevanis, Constantin N., Perez, Sonia A., Papamichail, Michael, and Peoples, George E.

Published
2020
Full Text
View/download PDF

21. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

Author

Souglakos, J., Boukovinas, I., Kakolyris, S., Xynogalos, S., Ziras, N., Athanasiadis, A., Androulakis, N., Christopoulou, A., Vaslamatzis, M., Ardavanis, A., Emmanouilides, C., Bompolaki, I., Kourousis, C., Makrantonakis, P., Christofyllakis, C., Athanasiadis, E., Kentepozidis, N., Karampeazis, A., Katopodi, U., Anagnosopoulos, A., Papadopoulos, G., Prinarakis, E., Kalisperi, A., Mavroudis, D., and Georgoulias, V.

Published
2019
Full Text
View/download PDF

22. 2107P Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients

Author

Tsoukalas, N.G., primary, Christopoulou, A.N., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, M., additional, Bokas, A., additional, Samelis, G.F., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Kalofonos, C., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Pentheroudakis, G., additional, Aravantinos, G., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2023
Full Text
View/download PDF

24. Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study

Author

Galiti, Dimitra, primary, Linardou, Helena, additional, Agelaki, Sofia, additional, Karampeazis, Athanasios, additional, Tsoukalas, Nikolaos, additional, Psyrri, Amanda, additional, Karamouzis, Michalis, additional, Syrigos, Konstantinos N., additional, Ardavanis, Alexandros, additional, Athanasiadis, Ilias, additional, Arvanitou, Eleni, additional, Sgourou, Stavroula, additional, Mala, Anastasia, additional, Vallilas, Christos, additional, and Boukovinas, Ioannis, additional

Published
2023
Full Text
View/download PDF

25. Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

Author

Dimitrios Balalis, Dimitrios Tsakogiannis, Eleni Kalogera, Stefania Kokkali, Elli Tripodaki, Alexandros Ardavanis, Dimitrios Manatakis, Dionysios Dimas, Nektarios Koufopoulos, Florentia Fostira, Dimitrios Korkolis, Ioannis Misitzis, Nikolaos Vassos, Chara Spiliopoulou, Dimitrios Vlachodimitropoulos, Garyfalia Bletsa, and Nikolaos Arkadopoulos

Subjects
angiogenesis, molecules, breast cancer, subtype, body mass index, menopausal status, Medicine
Abstract

Background: Angiogenesis is a hallmark of breast cancer (BC) and is mediated by the vascular endothelial growth factor (VEGF) signaling axis. It is regulated by different proangiogenic factors, including platelet-derived growth factor-CC (PDGF-CC) and heparin-binding EGF-like growth factor (HB-EGF), as well as co-receptors, such as neuropilin-1, which could have prognostic implications in BC patients. Patients and methods: We assessed the serum levels of VEGF, HB-EGF, PDGF-CC and neuropilin-1 in 205 patients with early BC (invasive, n = 187; in situ, n = 18) and in 31 healthy donors (HD) and investigated the potential associations with clinical and histopathological parameters. Results: VEGF serum levels were significantly higher in patients with invasive versus ductal carcinomas in situ. PDGF-CC serum concentrations varied among BC molecular subtypes. Furthermore, we observed a differential expression of most biomarkers between overweight/obese (body mass index (BMI) ≥ 25 kg/m2) and non-obese patients among the BC molecular subtypes. Finally, the classification of subjects according to menopausal status revealed a significant difference in specific biomarker levels between patients and HD. Conclusion: The serum concentrations of angiogenic molecules differ among breast cancer molecular subtypes and are affected by the BMI and menopausal status, which could have possible clinical or prognostic implications.

Published
2022
Full Text
View/download PDF

29. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

36. Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 'MELPOMENI' study)

Author

Athanasios, Alexopoulos, Charisios, Karanikiotis, Alexandros, Ardavanis, Ioannis, Boukovinas, Parisios, Makrantonakis, Christos, Papadimitriou, Athanasios, Athanasiadis, Anastasios, Boutis, Stylianos, Giassas, Stylianos, Kakolyris, Georgios, Koumakis, Konstantinos, Papazisis, Adamantia, Psyrri, Nikolaos, Ziras, Sofia, Baka, Nikolaos, Kentepozidis, and Vasiliki, Michalaki

Subjects
Aged, 80 and over, Cancer Research, Drug-Related Side Effects and Adverse Reactions, Greece, Receptor, ErbB-2, Breast Neoplasms, General Medicine, Middle Aged, Survival Analysis, Drug Administration Schedule, Postmenopause, Treatment Outcome, Receptors, Estrogen, Oncology, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Humans, Female, Everolimus, Neoplasm Metastasis, Neoplasm Recurrence, Local, Receptors, Progesterone, Aged
Abstract

This study aimed to provide real-world safety and effectiveness data of everolimus (EVE) plus exemestane (EXE) in estrogen receptor positive/human epidermal growth factor receptor 2 negative (ERThis prospective observational study was conducted by 19 hospital-based oncologists in Greece. Eligible patients were treated with EVE+EXE in the first-line setting; EVE was initiated according to the approved label.Overall, 75 eligible patients (mean age: 66.9 years; visceral metastases: 49.3%; bone-only metastases: 37.3%) were included in the effectiveness analyses. Over a median (interquartile range) of 12.1 months (range=4.2-20.5 months) of EVE treatment, the median progression-free survival was 18.0 months and the overall response rate was 22.7%. Among patients that received ≥1 EVE dose (n=80), the incidence of EVE-related adverse events was 72.5% (serious: 55.0%); stomatitis (22.5%), fatigue (22.5%), pneumonitis (18.8%); and cough (18.8%) were the most common.In the routine care in Greece, EVE demonstrates clinical benefit and a predictable safety profile.

Published
2022

38. Anatomic vs. reverse shoulder arthroplasty for the treatment of Walch B2 glenoid morphology: a systematic review and meta-analysis

Author

Emily J. Curry, Ryan L. Kim, Kyle S. Ardavanis, Joseph W. Galvin, Josef K. Eichinger, David Novikov, Xinning Li, G. Bradley Reahl, and Hussein Abdul-Rassoul

Subjects
medicine.medical_specialty, Walch B2 glenoid, RD1-811, Eccentric reaming, business.industry, medicine.medical_treatment, Elbow, Bone grafting, Arthroplasty, Confidence interval, Surgery, Total shoulder arthroplasty, Reverse shoulder arthroplasty, medicine.anatomical_structure, Glenohumeral osteoarthritis, Meta-analysis, medicine, Rotator cuff, Glenoid morphology, Posteriorly augmented glenoid component, Complication, business
Abstract

Background Walch B2 glenoid morphology with glenohumeral osteoarthritis is a difficult degenerative pattern to manage for shoulder surgeons. Anatomic total shoulder arthroplasty (TSA) in combination with eccentric reaming or bone grafting are the traditional methods of treatment. Newer approaches such as TSA with posteriorly augmented glenoid components and reverse shoulder arthroplasty (RSA) may offer better stability for the posteriorly subluxated biconcave B2 wear pattern. The aim of this systematic review is to compare mid-term surgical and functional outcomes of Walch B2 glenoids without significant rotator cuff pathology treated with TSA and RSA. Methods The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching the MEDLINE (PubMed) and Embase (Elsevier) databases. Inclusion criteria were clinical studies that evaluated the outcomes and complications of TSA or RSA in the setting of B2 glenoid morphology without significant rotator cuff pathology. Data relevant to TSA and RSA surgical outcomes were extracted and compiled, and outcomes were compared. A meta-analysis of proportions of complication and revision rates among TSA and RSA groups was performed. Results Overall, 16 articles were included with 414 TSAs and 78 RSAs. The average follow-up duration was 54.1 ± 14.8 months for patients undergoing TSA and 44.8 ± 10.1 months for patients undergoing RSA. The TSA group was further subdivided based on the use of eccentric reaming (135 TSAs), an augmented glenoid component (84 TSAs), or bone grafting (11 TSAs) or was unspecified (184 TSAs). Overall, patients undergoing TSA and RSA demonstrated mean improvements of 50.1 ± 8.5° and 64.7 ± 5.2° in active flexion, 58.5 ± 10.3° and 68.9 ± not reported° in active abduction, and 31.3 ± 5.7° and 29.0 ± 10.2° in active external rotation, respectively. In regard to functional outcome scores, patients undergoing TSA and RSA showed mean Constant score improvements of 38.8 ± 5.3 and 46.6 ± 3.1 points and American Shoulder and Elbow Surgeons score improvements of 48.2 ± 1.0 and 49.2 ± 25.3 points, respectively. Results of the meta-analysis with mid-term follow-up data demonstrated pooled complication rates of 9% (95% confidence interval [CI], 1%-22%) for TSA and 6% (95% CI, 0%-28%) for RSA and pooled revision rates of 2% (95% CI, 0%-8%) for TSA and 1% (95% CI, 0%-15%) for RSA. Conclusion In the setting of Walch B2 glenoid morphology, TSA with eccentric reaming or an augmented component yields comparable outcomes to RSA. Based on the patient's age, activity level, and expectations, both TSA and RSA can be considered a reasonable option to treat Walch B2 glenoid morphology.

Published
2021

40. 1585P Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies

Author

Tsoukalas, N.G., primary, Christopoulou, A.N., additional, Timotheadou, E., additional, Koumarianou, A., additional, Ardavanis, A., additional, Athanasiadis, I., additional, Demiri, M., additional, Bokas, A., additional, Samelis, G.F., additional, Peroukidis, S., additional, Papatsimpas, G., additional, Andreadis, C., additional, Nikolakopoulos, A., additional, Psyrri, A., additional, Kapodistrias, N., additional, Papakostas, P., additional, Aravantinos, G., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

41. EP10.01-018 Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial

Author

Tsoukalas, N., primary, Christopoulou, A., additional, Timotheadou, E., additional, Athanasiadis, I., additional, Koumarianou, A., additional, Peroukidis, S., additional, Samelis, G., additional, Psyrri, A., additional, Kapodistrias, N., additional, Nikolakopoulos, A., additional, Andreadis, C., additional, Ardavanis, A., additional, Kalofonos, C., additional, Samantas, E., additional, Papandreou, C., additional, Mavroudis, D., additional, Bokas, A., additional, Barbounis, V., additional, Kentepozidis, N., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

42. Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients

Author

Davies, Andrew, Buchanan, Alison, Zeppetella, Giovambattista, Porta-Sales, Josep, Likar, Rudolf, Weismayr, Wolfgang, Slama, Ondrej, Korhonen, Tarja, Filbet, Marilene, Poulain, Philippe, Mystakidou, Kyriaki, Ardavanis, Alexandros, O’Brien, Tony, Wilkinson, Pauline, Caraceni, Augusto, Zucco, Furio, Zuurmond, Wouter, Andersen, Steen, Damkier, Anette, Vejlgaard, Tove, Nauck, Friedemann, Radbruch, Lukas, Sjolund, Karl-Fredrik, and Stenberg, Mariann

Published
2013
Full Text
View/download PDF

43. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)

Author

Matikas, A., Kentepozidis, Ν., Ardavanis, A., Vaslamatzis, M., Polyzos, A., Emmanouilides, Ch., Katsaounis, P., Koinis, F., Xynogalos, S., Christopoulou, A., Ziras, N., Tegos, Th., Prinarakis, E., Hatzidaki, D., Georgoulias, V., Kotsakis, A., and on behalf of the HORG’s Lung Cancer Working Group

Published
2016
Full Text
View/download PDF

44. Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

Author

Balalis, Dimitrios, primary, Tsakogiannis, Dimitrios, additional, Kalogera, Eleni, additional, Kokkali, Stefania, additional, Tripodaki, Elli, additional, Ardavanis, Alexandros, additional, Manatakis, Dimitrios, additional, Dimas, Dionysios, additional, Koufopoulos, Nektarios, additional, Fostira, Florentia, additional, Korkolis, Dimitrios, additional, Misitzis, Ioannis, additional, Vassos, Nikolaos, additional, Spiliopoulou, Chara, additional, Vlachodimitropoulos, Dimitrios, additional, Bletsa, Garyfalia, additional, and Arkadopoulos, Nikolaos, additional

Published
2022
Full Text
View/download PDF

45. Prevention of venous thromboembolism in ambulatory patients with active cancer: Results from ACT4CAT study.

Author

Tsoukalas, Nikolaos, primary, Christopoulou, Athina, additional, Koumarianou, Anna, additional, Timotheadou, Eleni, additional, Athanasiadis, Ilias, additional, Samelis, Georgios, additional, Peroukidis, Stavros, additional, Psyrri, Amanda, additional, Kapodistrias, Nikolaos, additional, Nikolakopoulos, Achilleas, additional, Demiri, Stamatina G, additional, Andreadis, Charalampos, additional, Bokas, Alexandros, additional, Ardavanis, Alexandros, additional, Samantas, Epaminondas, additional, Mavroudis, Dimitrios, additional, Barbounis, Vasileios, additional, Athanasiadis, Athanasios, additional, Papakotoulas, Pavlos, additional, and Boukovinas, Ioannis, additional

Published
2022
Full Text
View/download PDF

46. PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study

Author

Tsoukalas, N., primary, Christopoulou, A., additional, Timotheadou, E., additional, Athanasiadis, I., additional, Koumarianou, A., additional, Peroukidis, S., additional, Samelis, G., additional, Psyrri, A., additional, Kapodistrias, N., additional, Nikolakopoulos, A., additional, Andreadis, C., additional, Ardavanis, A., additional, Samantas, E., additional, Papandreou, C., additional, Mavroudis, D., additional, Bokas, A., additional, Barbounis, V., additional, Kentepozidis, N., additional, Athanasiadis, A., additional, Papakotoulas, P., additional, and Boukovinas, I., additional

Published
2022
Full Text
View/download PDF

47. A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients’ Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece

Author

Stefania Kokkali, Ioannis Boukovinas, Epaminondas Samantas, Pavlos Papakotoulas, Ilias Athanasiadis, Charalampos Andreadis, Parisis Makrantonakis, Georgios Samelis, Eleni Timotheadou, Georgios Vassilopoulos, Christos Papadimitriou, Dimitrios Tzanninis, Alexandros Ardavanis, Ioannis Kotsantis, Kiki Karvounis-Marolachakis, Theodora Theodoropoulou, and Amanda Psyrri

Subjects
Cancer Research, Oncology, advanced soft tissue sarcoma, observational, quality of life, real-world, trabectedin
Abstract

This non-interventional, multicenter, prospective study aimed to evaluate the real-world activity of trabectedin, and its impact on symptom burden and quality of life in patients with advanced soft tissue sarcoma (aSTS) treated in routine clinical settings in Greece. Patients with histologically confirmed aSTS newly initiated on trabectedin were enrolled. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included PFS rate at 3 months, median PFS, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and an assessment of the impact of treatment on health-related quality of life (HRQoL), cancer-related symptom burden and symptom interference with function, as well as all-cause treatment discontinuation rate. A total of 64 eligible patients from 13 Greek centers were evaluated. Patients received a median of three trabectedin cycles per patient (interquartile range [IQR]: 2.0–6.0). Median PFS was 6.6 months with 67.9% and 51.2% of patients free from progression at 3 and 6 months, respectively. ORR was 7.8% and DCR 21.9%. Median OS was 13.1 months. No significant changes from enrolment were noted in HRQoL scores. In total, 30 patients (46.9%) had at least one trabectedin-related adverse drug reaction (ADR) and 9 (14.1%) at least one serious ADR. The treatment discontinuation rate due to toxicity was 9.4%. These results suggest that trabectedin is an active treatment with clinically meaningful benefits in patients with aSTS with no new safety signals.

Published
2022
Full Text
View/download PDF

48. Characteristics and outcomes of cancer patients who develop pulmonary embolism: A cross‑sectional study

Author

Serafeim Chlapoutakis, Vasiliki Georgakopoulou, Nikolaos Trakas, Georgios Kouvelos, Petros Papalexis, Christos Damaskos, Pagona Sklapani, Anastasios Grivas, Panagiotis Gouveris, Dimitrios Tryfonopoulos, Alexandros Tzovaras, Gerasimos Ardavanis‑Loukeris, Elissavet Grouzi, Demetrios Spandidos, and Miltiadis Matsagkas

Subjects
Cancer Research, Oncology
Abstract

Pulmonary embolism (PE), along with deep vein thrombosis, are collectively known as venous thromboembolism (VTE). Predisposing factors for PE include post-operative conditions, pregnancy, cancer and an advanced age; of note, a number of genetic mutations have been found to be associated with an increased risk of PE. The association between cancer and VTE is well-established, and cancer patients present a higher risk of a thrombotic event compared to the general population. In addition, PE is a significant cause of morbidity and mortality among cancer patients. The aim of the present study was to illustrate the clinical characteristics, laboratory findings, radiology features and outcomes of cancer patients who developed PE, collected from an anticancer hospital. For this purpose, adult cancer patients diagnosed with PE by imaging with computed tomography pulmonary angiography were enrolled. The following data were recorded: Demographics, comorbidities, type of cancer, time interval between cancer diagnosis and PE occurrence, the type of therapy received and the presence of metastases, clinical signs and symptoms, predisposing factors for PE development, laboratory data, radiological findings, electrocardiography findings, and the type of therapy received for PE and outcomes in a follow-up period of 6 months. In total, 60 cancer patients were enrolled. The majority of the cancer patients were males. The most common type of cancer observed was lung cancer. The majority of cases of PE occurred within the first year from the time of cancer diagnosis, while the majority of patients had already developed metastases. In addition, the majority of cancer patients had received chemotherapy over the past month, while they were not receiving anticoagulants and had central obstruction. A large proportion of patients had asymptomatic PE. The in-hospital mortality rate was 13.3% and no relapse or mortality were observed during the follow-up period. The present study demonstrates that elevated levels of lactic acid and an increased platelet count, as well as low serum levels of carcinoembryonic antigen, albumin and D-dimer, may be potential biomarkers for asymptomatic PE among cancer patients.

Published
2022

49. CureCancer Digital Platform in Clinical Oncology Practice Facilitates Patients’ Self-data Recording, Communicating, Treatment Adherence, 'Distancing Interventions' During Covid-19 and Reduces Costs. A Feasibility and Satisfaction Study

Author

Dimitra Galiti, Helena Linardou, Sofia Agelaki, Athanasios Karampeazis, Nikolaos Tsoukalas, Amanda Psyrri, Michalis Karamouzis, Konstantinos Syrigos, Alexandros Ardavanis, Ilias Athanasiadis, Eleni Arvanitou, Stavroula Sgourou, Vasileios Kouloulias, Anastasia Mala, Christos Vallilas, and Ioannis Boukovinas

Abstract

Background: Globally 43.8 million people live with cancer. A 60% increase of cancer cases is estimated by 2040, with 29.4 million patients per year requiring therapy. Optimization of cancer management, using digital innovation, is urgently needed. CureCancer is a patient-centric/driven platform, which enables patients to self-create their profile, report symptoms, and communicate with physicians. We assessed CureCancer’s feasibility and patients’ and HCPs’ satisfaction. Methods: Patients from 9 Centers were asked to register at CureCancer, upload their data and complete a questionnaire on demographics, disease and treatment characteristics, and their satisfaction. Results: 159 patients were enrolled and 144 (90.6%) registered. 114 of 144 (79.1%), 63 males and 51 females, median age 54.5 years, completed the questionnaire. 64 patients were University and 35 were high School graduates. 46 patients had metastatic disease, 87 were on active treatment and 51 received supportive care. All patients also visited non-oncology HCPs. Nineteen patients changed work status and 49 had children below 24 years. Registration was “very/very much” easy for 98 (86.0 %) patients. File uploading was “very/very much” easy for 47 (41.2%) patients. Over 80% of patients and physicians preferred the digital way. 99 patients and all HCPs will recommend CureCancer to others. Easy data access, improved communication, feeling safe, treatment adherence, interventions from distance, particularly during covid-19 pandemic and saving time and money, were highly commented by patients and HCPs. Conclusion: CureCancer was feasible, and patients and HCPs were satisfied. Patients were successful to report information on their demographics, disease and treatment characteristics. They also disclosed the need to visit non-oncology HCPs during their cancer treatment and other socioeconomic issues. Integration of CureCancer in the routine practice is expected to improve cancer care and reduce cancer costs. Patients’ self-reporting, with CureCancer, can increase the accuracy of clinical trial results and map social/work/economic issues following cancer diagnosis to assist health care policy.

Published
2022

50. The Addition of Mifamurtide To Adjuvant Chemotherapy For Early Osteosarcoma: A Retrospective Analysis From Greece

Author

Stefania Kokkali, Ioannis Kotsantis, Elpida Magou, Talagani Sophia, Theodoros Kormas, Giakoumis Diakoumis, Nikolaos Spathas, Amanda Psyrri, and Alexandros Ardavanis

Abstract

Background: Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The addition of mifamurtide to adjuvant cytotoxic chemotherapy was associated with a significant improvement in 6-year overall survival (OS) in young patients with resectable osteosarcoma, leading to its approval in Europe and other countries. Very limited real-world data are reported on its use.Methods: We retrospectively evaluated data from osteosarcoma patients who received mifamurtide in the adjuvant setting. Data were obtained from medical records in 2 high-volume bone sarcoma centers. The aim of this study was to collect real-world data on mifamurtide safety and efficacy in Greece. Results: We identified 15 patients with completely resected osteosarcoma who received mifamurtide from September 2015 to January 2020. Median age at diagnosis was 24 years old (16-76). Osteosarcoma arose in the lower extremities (n=12), in the upper extremities (n=2) or in the ilium (n=1). The majority of patients (n=13) received cisplatin/doxorubicin/methotrexate as perioperative chemotherapy and the remaining patients cisplatin/doxorubicin. After a median follow-up of 46.9 months (range, 32.8-61.1), the median recurrence-free survival was 58.7 months (range, 18.5-98.8) and the median OS 64.1 months (range, 25.6-102.6). Except for fever and chills, the only adverse event probably related to mifamurtide was pericarditis (n=1). Conclusions: Mifamurtide was well tolerated in a Greek osteosarcoma population, including patients older than 30 years. The small sample size and the non-comparative design do not allow drawing conclusions on the drug benefit in terms of survival.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results